|
業務類別
|
Biotechnology |
|
業務概覽
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA. |
| 公司地址
| 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801 |
| 電話號碼
| +1 781 222-9600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.replimune.com |
| 員工數量
| 479 |
| Mr. Paul Bullock |
Chief Manufacturing Officer |
-- |
26/03/2024 |
| Ms. Emily Hill |
Chief Financial Officer |
美元 266.54K |
22/05/2025 |
| Dr. Sushil Patel, PhD |
Director and Chief Executive Officer |
-- |
22/05/2025 |
| Mr. Andrew Schwendenman |
Chief Accounting Officer |
-- |
22/05/2025 |
| Dr. Konstantinos Xynos, M.D. |
Chief Medical Officer |
美元 499.20K |
19/07/2024 |
| Mr. Christopher Sarchi |
Chief Commercial Officer |
-- |
19/07/2024 |
|
|
| Mr. Michael Goller |
Independent Director |
22/05/2025 |
| Mr. Madhavan Balachandran |
Independent Director |
22/05/2025 |
| Ms. Veleka Peeples-Dyer |
Independent Director |
22/05/2025 |
| Dr. Sushil Patel, PhD |
Director and Chief Executive Officer |
22/05/2025 |
| Mr. Dieter Weinand |
Lead Independent Director |
22/05/2025 |
| Ms. Christy J. Oliger |
Independent Director |
22/05/2025 |
| Mr. Philip Astley-Sparke |
Executive Chairman of the Board |
22/05/2025 |
| Dr. Kapil Dhingra, M.B.B.S. |
Independent Director |
25/07/2025 |
| Mr. Paolo Pucci |
Independent Director |
22/05/2025 |
| Mr. Joseph P. Slattery, C.P.A. |
Independent Director |
22/05/2025 |
|
|
|
|
